Literature DB >> 22688362

Inhaled antibiotics in cystic fibrosis: what's new?

Simon Langton Hewer1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22688362      PMCID： PMC3372301          DOI： 10.1258/jrsm.2012.12s004

Source DB:  PubMed          Journal:  J R Soc Med        ISSN： 0141-0768            Impact factor:   5.344


× No keyword cloud information.
  25 in total

1.  Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease.

Authors:  Timothy D Murphy; Ran D Anbar; Lucille A Lester; Samya Z Nasr; Bruce Nickerson; Donald R VanDevanter; Andrew A Colin
Journal:  Pediatr Pulmonol       Date:  2004-10

2.  Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.

Authors:  David E Geller; Michael W Konstan; Jeffrey Smith; Sarah B Noonberg; Carol Conrad
Journal:  Pediatr Pulmonol       Date:  2007-04

3.  Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis.

Authors:  D S Armstrong; K Grimwood; J B Carlin; R Carzino; A Olinsky; P D Phelan
Journal:  Pediatr Pulmonol       Date:  1996-05

4.  Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohort.

Authors:  Margaret Rosenfeld; Julia Emerson; Sharon McNamara; Kelli Joubran; George Retsch-Bogart; Gavin R Graff; Hector H Gutierrez; Jamshed F Kanga; Thomas Lahiri; Blake Noyes; Bonnie Ramsey; Clement L Ren; Michael Schechter; Wayne Morgan; Ronald L Gibson
Journal:  Pediatr Pulmonol       Date:  2010-09

5.  Cystic fibrosis mortality and survival in the UK: 1947-2003.

Authors:  J A Dodge; P A Lewis; M Stanton; J Wilsher
Journal:  Eur Respir J       Date:  2006-12-20       Impact factor: 16.671

6.  Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis.

Authors:  Zhanhai Li; Michael R Kosorok; Philip M Farrell; Anita Laxova; Susan E H West; Christopher G Green; Jannette Collins; Michael J Rock; Mark L Splaingard
Journal:  JAMA       Date:  2005-02-02       Impact factor: 56.272

7.  Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis.

Authors:  G M Nixon; D S Armstrong; R Carzino; J B Carlin; A Olinsky; C F Robertson; K Grimwood
Journal:  J Pediatr       Date:  2001-05       Impact factor: 4.406

8.  Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.

Authors:  Miriam M Treggiari; Margaret Rosenfeld; Nicole Mayer-Hamblett; George Retsch-Bogart; Ronald L Gibson; Judy Williams; Julia Emerson; Richard A Kronmal; Bonnie W Ramsey
Journal:  Contemp Clin Trials       Date:  2009-01-15       Impact factor: 2.226

9.  Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis.

Authors:  Karen S McCoy; Alexandra L Quittner; Christopher M Oermann; Ronald L Gibson; George Z Retsch-Bogart; A Bruce Montgomery
Journal:  Am J Respir Crit Care Med       Date:  2008-07-24       Impact factor: 21.405

10.  Aztreonam (for inhalation solution) for the treatment of chronic lung infections in patients with cystic fibrosis: an evidence-based review.

Authors:  Stephen Kirkby; Kimberly Novak; Karen McCoy
Journal:  Core Evid       Date:  2011-08-11
View more
  5 in total

1.  Population pharmacokinetics of colistin methanesulfonate in rats: achieving sustained lung concentrations of colistin for targeting respiratory infections.

Authors:  Shalini Yapa; Jian Li; Christopher J H Porter; Roger L Nation; Kashyap Patel; Michelle P McIntosh
Journal:  Antimicrob Agents Chemother       Date:  2013-08-05       Impact factor: 5.191

2.  Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 2. Colistin.

Authors:  Aline Vidal Lacerda Gontijo; Nicolas Grégoire; Isabelle Lamarche; Patrice Gobin; William Couet; Sandrine Marchand
Journal:  Antimicrob Agents Chemother       Date:  2014-05-05       Impact factor: 5.191

3.  Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 1. Ciprofloxacin, moxifloxacin, and grepafloxacin.

Authors:  Aline Vidal Lacerda Gontijo; Julien Brillault; Nicolas Grégoire; Isabelle Lamarche; Patrice Gobin; William Couet; Sandrine Marchand
Journal:  Antimicrob Agents Chemother       Date:  2014-05-05       Impact factor: 5.191

Review 4.  Current and future treatment options for cystic fibrosis lung disease: latest evidence and clinical implications.

Authors:  Claire Edmondson; Jane C Davies
Journal:  Ther Adv Chronic Dis       Date:  2016-05-01       Impact factor: 5.091

5.  The Antibacterial and Anti-inflammatory Activity of Chicken Cathelicidin-2 combined with Exogenous Surfactant for the Treatment of Cystic Fibrosis-Associated Pathogens.

Authors:  Brandon J H Banaschewski; Brandon Baer; Christina Arsenault; Teah Jazey; Edwin J A Veldhuizen; Johan Delport; Tracey Gooyers; James F Lewis; Henk P Haagsman; Ruud A W Veldhuizen; Cory Yamashita
Journal:  Sci Rep       Date:  2017-11-14       Impact factor: 4.379
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.